Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1805, Issue 1, 2010, Pages 17-24

  Lamoureux, F ^a   Moriceau, G ^a   Picarda, G ^a   Rousseau, J ^a   Trichet, V ^a   Redini F ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Bone resorption; Bone tumor; OPG; Proteoglycan; RANKL; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOSAMINOGLYCAN; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; PROTEOGLYCAN; RECOMBINANT OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOAVAILABILITY; BONE REMODELING; BONE TUMOR; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG POTENTIATION; HUMAN; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SINGLE DRUG DOSE;

EID: 75349090418     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.08.004     Document Type: Review

References (91)

1. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27 (2001) 165-176
2. Lamoureux F., Trichet V., Chipoy C., Blanchard F., Gouin F., and Rédini F. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev. Anticancer. Ther 7 (2007) 169-181
3. Guise T.A. The vicious cycle of bone metastases. J. Musculoskelet. Neuronal Interact. 2 (2002) 570-572
4. Lamoureux F., Richard P., Wittrant Y., Battaglia S., Pilet P., Trichet V., Blanchard F., Gouin F., Pitard B., Heymann D., and Rédini F. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 67 (2007) 7308-7318
5. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
6. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95 (1998) 3597-3602
7. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., and Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
8. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Lüthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
9. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998) 1329-1337
10. Baud'huin M., Duplomb L., Ruiz Velasco C., Fortun Y., Heymann D., and Padrines M. Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev. Anticancer Ther. 7 (2007) 221-232
11. Dougall W.C., and Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 25 (2006) 541-549
12. Theoleyre S., Wittrant Y., Kwan Tat S., Fortun Y., Rédini F., and Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 15 (2004) 457-475
13. Walsh M.C., and Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 14 (2003) 251-263
14. Morony S., Capparelli C., Sarosi I., Lacey D.L., Dunstan C.R., and Kostenuik P.J. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61 (2001) 4432-4436
15. Body J.J., Greipp P., Coleman R.E., Facon T., Geurs F., Fermand J.P., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (2003) 887-892
16. Wittrant Y., Theoleyre S., Chipoy C., Padrines M., Blanchard F., Heymann D., and Rédini F. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim. Biophys. Acta 1704 (2004) 49-57
17. Holen I I., and Shipman C.M. Role of osteoprotegerin (OPG) in cancer. Clin. Sci. (Lond) 110 (2006) 279-291
18. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., and Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273 (1998) 14363-14367
19. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., and Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15 (2000) 2-12
20. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.J., and Simonet W.S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12 (1998) 1260-1268
21. Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., Van G., Kaufman S., Kostenuik P.J., Lacey D.L., Boyle W.J., and Simonet W.S. WS, Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp. Med 192 (2000) 463-474
22. Akatsu T., Murakami T., Nishikawa M., Ono K., Shinomiya N., Tsuda E., Mochizuki S., Yamaguchi K., Kinosaki M., Higashio K., Yamamoto M., Motoyoshi K., and Nagata N. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem. Biophys. Res. Commun. 250 (1998) 229-234
23. Brown J.M., Corey E., Lee Z.D., True L.D., Yun T.J., Tondravi M., and Vessella R.L. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57 (2001) 611-616
24. Farrugia A.N., Atkins G.J., To L.B., Pan B., Horvath N., Kostakis P., Findlay D.M., Bardy P., and Zannettino A.C. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63 (2003) 5438-5445
25. Huang L., Cheng Y.Y., Chow L.T., Zheng M.H., and Kumta S.M. Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases. J. Clin. Pathol. 55 (2002) 877-878
26. Michigami T., Ihara-Watanabe M., Yamazaki M., and Ozono K. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res. 61 (2001) 1637-1644
27. Nosaka K., Miyamoto T., Sakai T., Mitsuya H., Suda T., and Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood 99 (2002) 634-640
28. Guise T.A. Molecular mechanisms of osteolytic bone metastases. Cancer 88 (2000) 2892-2898
29. Chirgwin J.M., and Guise T.A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit. Rev. Eukaryot. Gene Expr. 10 (2000) 159-178
30. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2 (2002) 584-593
31. Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 350 (2004) 1655-1664
32. Mori K., Le Goff B., Charrier C., Battaglia S., Heymann D., and Rédini F. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone 40 (2007) 981-990
33. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla C.V., Komnenovic V., Kong Y.Y., Schreiber M., Dixon S.J., Sims S.M., Khokha R., Wada T., and Penninger J.M. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440 (2006) 692-696
34. Armstrong A.P., Miller R.E., Jones J.C., Zhang J., Keller E.T., and Dougall W.C. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68 (2008) 92-104
35. Price P.A., June H.H., Buckley J.R., and Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1610-1616
36. Clohisy D.R., Ramnaraine M.L., Scully S., Qi M., Van G., Tan H.L., and Lacey D.L. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J. Orthop. Res. 18 (2000) 967-976
37. Capparelli C., Kostenuik P.J., Morony S., Starnes C., Weimann B., Van G., Scully S., Qi M., Lacey D.L., and Dunstan C.R. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 60 (2000) 783-787
38. Akatsu T., Murakami T., Ono K., Nishikawa M., Tsuda E., Mochizuki S.I., Fujise N., Higashio K., Motoyoshi K., Yamamoto M., and Nagata N. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 23 (1998) 495-498
39. Honore P., Luger N.M., Sabino M.A., Schwei M.J., Rogers S.D., Mach D.B., O'keefe P.F., Ramnaraine M.L., Clohisy D.R., and Mantyh P.W. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat. Med. 6 (2000) 521-528
40. Roudier M.P., Bain S.D., and Dougall W.C. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. Clin. Exp. Metastasis 23 (2006) 167-175
41. Canon J.R., Roudier M., Bryant R., Morony S., Stolina M., Kostenuik P.J., and Dougall W.C. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin. Exp. Metastasis 25 (2008) 119-129
42. Croucher P.I., Shipman C.M., Lippitt J., Perry M., Asosingh K., Hijzen A., Brabbs A.C., van Beek E.J., Holen I., Skerry T.M., Dunstan C.R., Russell G.R., Van Camp B., and Vanderkerken K. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98 (2001) 3534-3540
43. Croucher P.I., Shipman C.M., Van Camp B., and Vanderkerken K. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 97 (2003) 818-824
44. Jung K., Stephan C., Semjonow A., Lein M., Schnorr D., and Loening S.A. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J. Urol. 170 (2003) 2302-2305
45. Kiefer J.A., Vessella R.L., Quinn J.E., Odman A.M., Zhang J., Keller E.T., Kostenuik P.J., Dunstan C.R., and Corey E. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin. Exp. Metastasis 21 (2004) 381-387
46. Vanderkerken K., De Leenheer E., Shipman C., Asosingh K., Willems A., Van Camp B., and Croucher P. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 63 (2003) 287-289
47. Tannehill-Gregg S.H., Levine A.L., Nadella M.V., Iguchi H., and Rosol T.J. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin. Exp. Metastasis 23 (2006) 19-31
48. Quinn J.E., Brown L.G., Zhang J., Keller E.T., Vessella R.L., and Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis. 8 (2005) 253-259
49. Zheng Y., Zhou H., Brennan K., Blair J.M., Modzelewski J.R., Seibel M.J., and Dunstan C.R. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40 (2007) 471-478
50. Kostenuik P.J., Bolon B., Morony S., Daris M., Geng Z., Carter C., and Sheng J. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 34 (2004) 656-664
51. Bolon B., Carter C., Daris M., Morony S., Capparelli C., Hsieh A., Mao M., Kostenuik P.J., Dunstan C.R., Lacey D.L., and Sheng J.Z. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol. Ther. 3 (2001) 197-205
52. Ulrich-Vinther M., Carmody E.E., Goater J.J., balle K.S., O'Keefe R.J., and Schwarz E.M. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J. Bone Joint Surg. Am 84-A (2002) 1405-1412
53. Yang S.Y., Mayton L., Wu B., Goater J.J., Schwarz E.M., and Wooley P.H. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. Arthritis Rheum 46 (2002) 2514-2523
54. Chanda D., Isayeva T., Kumar S., Siegal G.P., Szafran A.A., Zinn K.R., Reddy V.V., and Ponnazhagan S. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol. Ther. 16 (2008) 871-878
55. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., and Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16 (2001) 348-360
56. Body J.J. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 97 (2003) 859-865
57. Van Poznak C., Cross S.S., Saggese M., Hudis C., Panageas K.S., Norton L., Coleman R.E., and Holen I. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J. Clin. Pathol. 59 (2006) 56-63
58. Locklin R.M., Croucher P.I., Russell R.G., and Edwards C.M. Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. Leukemia 21 (2007) 805-812
59. Shipman C.M., and Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63 (2003) 912-916
60. Holen I., Croucher P.I., Hamdy F.C., and Eaton C.L. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62 (2002) 1619-1623
61. Nyambo R., Cross N., Lippitt J., Holen I., Bryden G., Hamdy F.C., and Eaton C.L. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J. Bone Miner. Res. 19 (2004) 1712-1721
62. Holen I., Cross S.S., Neville-Webbe H.L., Cross N.A., Balasubramanian S.P., Croucher P.I., Evans C.A., Lippitt J.M., Coleman R.E., and Eaton C.L. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo-a role in tumour cell survival?. Breast Cancer Res. Treat. 92 (2005) 207-215
63. Neville-Webbe H.L., Cross N.A., Eaton C.L., Nyambo R., Evans C.A., Coleman R.E., and Holen I. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res. Treat. 86 (2004) 269-279
64. Chamoux E., Houde N., L'Eriger K., and Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J. Cell Physiol. 216 (2008) 536-542
65. Brunetti G., Oranger A., Mori G., Tamma R., Di Benedetto A., Pignataro P., Grassi F.R., Zallone A., Grano M., and Colucci S. TRAIL is involved in human osteoclast apoptosis. Ann. N.Y. Acad. Sci. 1116 (2007) 316-322
66. Colucci S., Brunetti G., Cantatore F.P., Oranger A., Mori G., Pignataro P., Tamma R., Grassi F.R., Zallone A., and Grano M. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis 12 (2007) 1623-1632
67. Brunetti G., Colucci S., Rizzi R., Mori G., Colaianni G., Oranger A., Zallone A., Liso V., and Grano M. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease. Ann. N.Y. Acad. Sci. 1068 (2006) 334-340
68. Colucci S., Brunetti G., Rizzi R., Zonno A., Mori G., Colaianni G., Del Prete D., Faccio R., Liso A., Capalbo S., Liso V., Zallone A., and Grano M. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 104 (2004) 3722-3730
69. Tinhofer I., Biedermann R., Krismer M., Crazzolara R., and Greil R. A role of TRAIL in killing osteoblasts by myeloma cells. Faseb J. 20 (2006) 759-761
70. Zauli G., Rimondi E., Nicolin V., Melloni E., Celeghini C., and Secchiero P. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104 (2004) 2044-2050
71. Zauli G., Rimondi E., Stea S., Baruffaldi F., Stebel M., Zerbinati C., Corallini F., and Secchiero P. TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J. Cell Physiol. 214 (2008) 117-125
72. Zauli G., Rimondi E., and Secchiero P. Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin. J. Cell. Mol. Med. 12 (2008) 1063-1065
73. Labrinidis A., Liapis V., Thai le M., Atkins G.J., Vincent C., Hay S., Sims N.A., Zannettino A.C., Findlay D.M., and Evdokiou A. Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?. Blood 111 (2008) 5411-5412 autor reply 5413
74. Thai le M., Labrinidis A., Hay S., Liapis V., Bouralexis S., Welldon K., Coventry B.J., Findlay D.M., and Evdokiou A. Apo2l/tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res. 66 (2006) 5363-5370
75. Yen M.L., Tsai H.F., Wu Y.Y., Hwa H.L., Lee B.H., and Hsu P.N. TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells. Mol. Immunol. 45 (2008) 2205-2213
76. Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M.P., Deen K.C., McLaughlin M.M., Srinivasula S.M., Livi G.P., Marshall L.A., Alnemri E.S., Williams W.V., and Doyle M.L. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. 275 (2000) 23319-23325
77. Vitovski S., Phillips J.S., Sayers J., and Croucher P.I. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J. Biol. Chem. 282 (2007) 31601-31609
78. Schneeweis L.A., Willard D., and Milla M.E. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J. Biol. Chem. 280 (2005) 41155-41164
79. Cheng X., Kinosaki M., Takami M., Choi Y., Zhang H., and Murali R. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J. Biol. Chem. 279 (2004) 8269-8277
80. Heath D.J., Vanderkerken K., Cheng X., Gallagher O., Prideaux M., Murali R., and Croucher P.I. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res 67 (2007) 202-208
81. Lamoureux F., Picarda G., Garrigue-Antar L., Baud'huin M., Trichet V., Vidal A., Miot-Noirault E., Pitard B., Heymann D., and Rédini F. Cancer Res. 69 (2009) 526-536
82. Fisher J.L., Thomas-Mudge R.J., Elliott J., Hards D.K., Sims N.A., Slavin J., Martin T.J., and Gillespie M.T. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 66 (2006) 3620-3628
83. Sanderson R.D., Yang Y., Suva L.J., and Kelly T. Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol. 23 (2004) 341-352
84. Yip G.W., Smollich M., and Gotte M. Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Ther. 5 (2006) 2139-2148
85. Bernfield M., Gotte M., Park W.P., Reizes O., Fitzgerald M.L., Lincecum J., and Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68 (1999) 729-777
86. Standal T., Seidel C., Hjertner O., Plesner T., Sanderson R.D., Waage A., Borset M., and Sundan A. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100 (2002) 3002-3007
87. Mosheimer B.A., Kaneider N.C., Feistritzer C., Djanani A.M., Sturn D.H., Patsch J.R., and Wiedermann C.J. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J. Clin. Endocrinol. Metab. 90 (2005) 2964-2971
88. Theoleyre S., Kwan Tat S., Vusio P., Blanchard F., Gallagher J., Ricard-Blum S., Fortun Y., Padrines M., Rédini F., and Heymann D. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem. Biophys. Res. Commun. 347 (2006) 460-467
89. Irie A., Takami M., Kubo H., Sekino-Suzuki N., Kasahara K., and Sanai Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 41 (2007) 165-174
90. Lamoureux F., Baud'huin M., Duplomb L., Heymann D., and Rédini F. Proteoglycans: key partners in bone cell biology. Bioessays 29 (2007) 758-771
91. Shinmyouzu K., Takahashi T., Ariyoshi W., Ichimiya H., Kanzaki S., and Nishihara T. Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-kappa B ligand. Biochem. Biophys. Res. Commun. 354 (2007) 447-452